Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 5/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17870942 | 1.00 | GLS (0.46) | GLSLMNAADORA3IDH1SCD5 | |
| SCHEMBL12333636 | 1.00 | GLS (0.46) | GLSLMNAADORA3IDH1SCD5 | |
| SCHEMBL14665075 | 0.87 | GLS (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL14665079 | 0.87 | GLS (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL8138150 | 0.83 | HDAC1 (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL6948748 | 0.83 | GLS (0.42) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL14665118 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 | |
| SCHEMBL14665137 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 | |
| SCHEMBL6433693 | 0.83 | POLB (0.42) | GLSSCD5NPSR1 | |
| SCHEMBL15743835 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-07-20 | — | — | US | disclosed |
| US-9340574-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2015-08-27 | — | — | US | disclosed |
| US-20140186378-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186378-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-07-03 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8586051-B2 | Glycolipids and analogues thereof as antigens for NKT cells | THE ROCKEFELLER UNIVERSITY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| EP-1995240-B1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110086053-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2011-04-14 | — | — | US | disclosed |
| US-7923013-B2 | Glycolipids and analogues thereof as antigens for NKT cells | THE ROCKEFELLER UNIVERSITY (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1995240-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008128062-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS | THE ROCKEFELLER UNIVERSITY (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | GLS 2285/4885LMNA 4285/4885ADORA3 4138/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | GLS 2285/4885LMNA 4285/4885ADORA3 4138/4885 |
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | GLS 400/4885LMNA 1106/4885ADORA3 3707/4885 |
| US-20110086053-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | CD69, KLRK1, PBK | GLS 2993/4885LMNA 3257/4885ADORA3 2437/4885 |
| US-20150239931-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTP4A2, PTPRF, PTPA | GLS 2621/4885LMNA 4771/4885ADORA3 4839/4885 |
| US-20140186378-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NKT CELLS | CD69, KLRK1, PBK | GLS 2993/4885LMNA 3257/4885ADORA3 2437/4885 |
| US-20090197834-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY12, P2RY11, P2RY10 | GLS 1942/4885LMNA 4180/4885ADORA3 93/4885 |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | CD69, KLRK1, PBK | GLS 2993/4885LMNA 3257/4885ADORA3 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.